$XBI $135 +1%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Pipeline Updates
$DRRX +0% DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL). source
$ATOS -28% Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated. source
$AVDL +1% Avadel Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy at SLEEP 2021. source
$OMER +1% OMEROS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1 CLINICAL TRIAL OF OMS906. source
$ARNA +2% ARENA PHARMACEUTICALS ANNOUNCES ORPHAN DRUG DESIGNATION FOR ETRASIMOD FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EOE). source
$SCYX -1% SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections. source
$INZY +1% Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency. source
$ADMS -1% FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021. source
Posted by DV